IL34670A - תכשירי רוקחות המכילים 2-)2,6- דיכלורופניל-אמינו( -1,3- דיאזאציקופנטן-)2( ו/או מלחי סיפוח חומצתיים שלו - Google Patents
תכשירי רוקחות המכילים 2-)2,6- דיכלורופניל-אמינו( -1,3- דיאזאציקופנטן-)2( ו/או מלחי סיפוח חומצתיים שלוInfo
- Publication number
- IL34670A IL34670A IL34670A IL3467070A IL34670A IL 34670 A IL34670 A IL 34670A IL 34670 A IL34670 A IL 34670A IL 3467070 A IL3467070 A IL 3467070A IL 34670 A IL34670 A IL 34670A
- Authority
- IL
- Israel
- Prior art keywords
- dichlorophenyl
- compositions
- amino
- diazacyclopentene
- acid addition
- Prior art date
Links
- 239000002253 acid Substances 0.000 title claims description 8
- 150000003839 salts Chemical class 0.000 title claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 7
- 239000000203 mixture Substances 0.000 claims description 16
- 206010027599 migraine Diseases 0.000 claims description 15
- 208000019695 Migraine disease Diseases 0.000 claims description 14
- 239000004480 active ingredient Substances 0.000 claims description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- -1 2 , 6-dichlorophenyl-amino Chemical group 0.000 claims description 3
- 229910002651 NO3 Inorganic materials 0.000 claims description 3
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 238000007911 parenteral administration Methods 0.000 claims description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000001077 hypotensive effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000002082 anti-convulsion Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000002249 decongestive effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 230000003639 vasoconstrictive effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE1928798A DE1928798C3 (de) | 1969-06-06 | 1969-06-06 | Verwendung von 2-(2,6-Dichlorphenylamino)-1,3-diazacyclopenten-(2) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL34670A0 IL34670A0 (en) | 1970-08-19 |
| IL34670A true IL34670A (he) | 1972-10-29 |
Family
ID=5736237
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL34670A IL34670A (he) | 1969-06-06 | 1970-06-05 | תכשירי רוקחות המכילים 2-)2,6- דיכלורופניל-אמינו( -1,3- דיאזאציקופנטן-)2( ו/או מלחי סיפוח חומצתיים שלו |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US3666861A (he) |
| AU (1) | AU525754B2 (he) |
| BE (1) | BE751577A (he) |
| CA (1) | CA943462A (he) |
| DE (1) | DE1928798C3 (he) |
| FR (1) | FR2052939A1 (he) |
| GB (1) | GB1310171A (he) |
| IE (1) | IE34728B1 (he) |
| IL (1) | IL34670A (he) |
| NL (1) | NL161965C (he) |
| ZA (1) | ZA703692B (he) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4201211A (en) * | 1977-07-12 | 1980-05-06 | Alza Corporation | Therapeutic system for administering clonidine transdermally |
| US4587257A (en) * | 1984-12-14 | 1986-05-06 | Alcon Laboratories, Inc. | Control of ocular bleeding using clonidine derivatives |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3236857A (en) * | 1961-10-09 | 1966-02-22 | Boehringer Sohn Ingelheim | 2-(phenyl-amino)-1, 3-diazacyclopentene-(2) substitution products |
-
1969
- 1969-06-06 DE DE1928798A patent/DE1928798C3/de not_active Expired
-
1970
- 1970-06-02 ZA ZA703692A patent/ZA703692B/xx unknown
- 1970-06-03 US US43197A patent/US3666861A/en not_active Expired - Lifetime
- 1970-06-04 NL NL7008117.A patent/NL161965C/xx not_active IP Right Cessation
- 1970-06-04 GB GB2706270A patent/GB1310171A/en not_active Expired
- 1970-06-04 AU AU15931/70A patent/AU525754B2/en not_active Expired
- 1970-06-05 IE IE729/70A patent/IE34728B1/xx unknown
- 1970-06-05 FR FR7020728A patent/FR2052939A1/fr not_active Withdrawn
- 1970-06-05 IL IL34670A patent/IL34670A/he unknown
- 1970-06-05 CA CA084,759A patent/CA943462A/en not_active Expired
- 1970-06-05 BE BE751577D patent/BE751577A/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| NL161965C (nl) | 1980-03-17 |
| GB1310171A (en) | 1973-03-14 |
| IL34670A0 (en) | 1970-08-19 |
| US3666861A (en) | 1972-05-30 |
| ZA703692B (en) | 1971-02-24 |
| DE1928798C3 (de) | 1981-06-11 |
| DE1928798B2 (de) | 1980-06-19 |
| DE1928798A1 (de) | 1970-12-17 |
| AU525754B2 (en) | 1982-12-02 |
| IE34728L (en) | 1970-12-06 |
| NL161965B (nl) | 1979-10-15 |
| FR2052939A1 (he) | 1971-04-16 |
| NL7008117A (he) | 1970-12-08 |
| IE34728B1 (en) | 1975-08-06 |
| BE751577A (fr) | 1970-12-07 |
| CA943462A (en) | 1974-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS60105617A (ja) | 骨炎及び骨髄炎予防治療組成物 | |
| US4438138A (en) | Reduction of cholesterol with meta-chloro α-t-butylaminopropiophenone | |
| EP0269303A2 (en) | Piperidine derivative for treating pain | |
| US4387093A (en) | Arthritis treatment | |
| US4027017A (en) | Method of treating alcoholism | |
| IL34670A (he) | תכשירי רוקחות המכילים 2-)2,6- דיכלורופניל-אמינו( -1,3- דיאזאציקופנטן-)2( ו/או מלחי סיפוח חומצתיים שלו | |
| US4650668A (en) | Composition for relieving toothache pain and other forms of intense pain | |
| US5026706A (en) | Method for treating dysuria using naftopidil | |
| US3644643A (en) | Method of reducing intraocular pressure using glycine | |
| US20010029262A1 (en) | Method of treatment or prophylaxis | |
| JPH08239327A (ja) | 慢性骨格筋疼痛の予防又は治療剤 | |
| KR890014109A (ko) | 의약제 | |
| Car et al. | A double-blind multicentre comparison of diclofenac sodium and naproxen in osteoarthrosis of the hip | |
| US5081153A (en) | Sterile parenteral composition | |
| EP0256629A2 (en) | Tolrestat or a salt thereof as an immuno-stimulating agent | |
| KR20010021796A (ko) | 선택성 세로토닌 재흡수 억제제 (ｓｓｒｉ)를 사용하는심장 질환의 치료 및 예방법 | |
| US4302452A (en) | Use of derivatives of 6α-methylprednisolone as an antiemetic | |
| US4062974A (en) | Method for treating drepanocytosis | |
| EP1121124A1 (en) | Pharmaceutical combination of ibuprofen-lysine and domperidone for treating migraine | |
| JP2003171266A (ja) | キシリトールを含有する解熱性調剤 | |
| US4663345A (en) | Etodolac for treatment of gout | |
| US2995489A (en) | Method of obtaining preanesthetic sedation and drying with 1-(2-diethylaminoethyl)-5-ethyl-5-phenylbarbituric acid | |
| CA2840521A1 (en) | Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation | |
| JP2000229853A (ja) | 生理痛改善用組成物 | |
| EP0365134A1 (en) | Synergistic compositions of renal dopaminergic agent and angiotensin converting enzyme inhibitors |